BioCardia, Inc. Share Price
NASDAQ: BCDA | Micro CapBioCardia, Inc. Stock Performance
Open $0.91 | Prev. Close $0.96 | Circuit Range N/A |
Day Range $0.90 - $0.94 | Year Range $0.76 - $2.29 | Volume 760 |
Average Traded $0.92 |
BioCardia, Inc. Share Price Today
As of 9 August 2026, BioCardia, Inc.'s share price is $0.96. The stock opened at $0.91, compared to its previous close of $0.96. During today's trading session, BioCardia, Inc.'s share price traded between $0.90 and $0.94, with an average price of $0.92. Over the past 52 weeks, the stock has recorded a high of $2.29 and a low of $0.76. In terms of performance, BioCardia, Inc.'s share price has declined by 26.44% over the last six months and is down 51.27% on a year-on-year basis.
BioCardia, Inc. Share Price Chart
BioCardia, Inc. Stock Fundamentals & Key Indicators
Market Cap $6.40M | PE Ratio (TTM) -0.78 | Dividend Yield N/A |
EPS (TTM) $-1.23 | Revenue (TTM) N/A | Return On Equity (TTM) -919.33% |
Profit Margin N/A | Debt to Equity 2.72 | Quarterly Earnings Growth YoY 14.62% |
BioCardia, Inc. Quarterly Profit & Loss
All figures in USD
BioCardia, Inc. Annual Profit & Loss
All figures in USD
About BioCardia, Inc.
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths products. It has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.
BioCardia, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $0.85 | $0.94 | +16.25% |
Jul 2026 | $1.21 | $0.81 | -35.52% |
Jun 2026 | $0.90 | $1.25 | +35.72% |
May 2026 | $1.13 | $0.92 | -19.91% |
Apr 2026 | $1.17 | $1.15 | -1.29% |
Mar 2026 | $1.35 | $1.17 | -10.73% |
Feb 2026 | $1.12 | $1.30 | +6.10% |
Jan 2026 | $1.26 | $1.23 | -1.60% |
Dec 2025 | $1.42 | $1.25 | -12.89% |
Nov 2025 | $1.41 | $1.44 | +3.24% |
Oct 2025 | $1.33 | $1.39 | +6.51% |
Sep 2025 | $1.94 | $1.30 | -33.76% |
BCDA Share Price FAQs
What is BioCardia, Inc. share price today?
What is the 52 week high and 52 week low of BioCardia, Inc. stock?
What is BCDA's market capitalisation today?
What is BCDA's net income for the last quarter?
What is the 5 year returns of BCDA?
What is the high & low stock price of BCDA today?
Can I buy BCDA shares in India?